Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Part of paid clinical trials in Glendale, Arizona.

Sponsor
AbbVie
Study ID
NCT03478787
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
All
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Key Dates

Start date
May 8, 2018
Status verified
Jun 2021
Primary completion
Jul 8, 2020
Completion
Jul 8, 2020

Study Design

Enrollment
327 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Risankizumab
    Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
  • Active Comparator: Secukinumab
    Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.

Primary Outcome Measure

Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16 [ Time Frame: Week 16 ]

Locations (28)

FacilityCityStateZIPSite coordinators
Advanced Research Associates - Glendale /ID# 204335GlendaleArizona85308-
Alliance Dermatology and MOHs /ID# 204336PhoenixArizona85032-
Bakersfield Derma & Skin Cance /ID# 202115BakersfieldCalifornia93309-
Center for Dermatology Clin Res /ID# 202116FremontCalifornia94538-
Dermatology Res. Assoc., CA /ID# 202170Los AngelesCalifornia90045-
UC Davis Health /ID# 202263SacramentoCalifornia95816-
Medderm Associates /ID# 202162San DiegoCalifornia92103-
UConn Health Main /ID# 201745FarmingtonConnecticut06032-
Tory P Sullivan, MD PA /ID# 202177North Miami BeachFlorida33162-4708-
Renstar Medical Research /ID# 202113OcalaFlorida34470-
Progressive Medical Research /ID# 202183Port OrangeFlorida32127-
Integrated Clinical Research LLC /ID# 202152West Palm BeachFlorida33406-6063-
Dermatology Specialists Resear /ID# 202145LouisvilleKentucky40241-
Dermatology and Skin Cancer Specialists, LLC /ID# 203938RockvilleMaryland20850-
ORA, Inc. /ID# 204342AndoverMassachusetts01810-
Beth Israel Deaconess Medical Center /ID# 204340BostonMassachusetts02215-5400-
Minnesota Clinical Study Center /ID# 202369New BrightonMinnesota55112-
Central Dermatology, PC /ID# 202156St LouisMissouri63117-
Psoriasis Treatment Ctr of Central NJ /ID# 202107East WindsorNew Jersey08520-
Synexus Research Cincinnati /ID# 202161CincinnatiOhio45236-
Oregon Derm & Res. Ctr /ID# 201652PortlandOregon97210-
Oregon Medical Res Center PC /ID# 201651PortlandOregon97223-
Clinical Partners, LLC /ID# 201736JohnstonRhode Island02919-
Center for Clinical Studies - Houston (Binz) /ID# 202178HoustonTexas77004-8097-
Progressive Clinical Research /ID# 202155San AntonioTexas78229-
Center for Clinical Studies - Webster TX /ID# 202154WebsterTexas77598-
University of Utah /ID# 204035Salt Lake CityUtah84112-5500-
Froedtert Mem Lutheran Hosp /ID# 204896MilwaukeeWisconsin53226-

Find similar trials in Glendale, AZ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Advanced Research Associates - Glendale· Glendale, AZAlliance Dermatology and MOHs· Phoenix, AZBakersfield Derma & Skin Cance· Bakersfield, CACenter for Dermatology Clin Res· Fremont, CADermatology Res. Assoc., CA· Los Angeles, CAUC Davis Health· Sacramento, CA

Related Studies